TY - JOUR
AU - Tuma, Rabiya S.
AB - NEWS Cervical Cancer: The Second-Generation Vaccines Move Forward By Rabiya S. Tuma he quadrivalent human papillomavi- ing substantial progress and expect to start is 10 times that level or 1000 times above rus (HPV) vaccine is nearly 100% phase I clinical trials sometime next year. that, as long as we still get protection.” Teffective at protecting against precan- In this issue of the Journal, Richard To maximize immune responses, the cerous cervical lesions caused by the HPV Roden, Ph.D. , associate professor of pathol- investigators will incorporate an adjuvant into the vaccine formulation. Once they types included in the vaccine, which was ogy at Johns Hopkins University in decide what adjuvant to use, they expect to approved by the U.S. Food and Drug Baltimore, and colleagues report on one launch phase I clinical trials. The NCI – Administration in 2006. But experts agree such effort. Working with the Schiller/Lowy Hopkins team has patented the approach that both the quadrivalent vaccine (Gardasil) group at NCI, the researchers are building and licensed it to Shantha Biotech, which — and a bivalent vaccine approved in Europe a vaccine by using the minor capsid protein will manufacture the vaccine for trials in and 
TI - Cervical Cancer: The Second-Generation Vaccines Move Forward
JF - JNCI: Journal of the National Cancer Institute
DO - 10.1093/jnci/djp152
DA - 2009-06-02
UR - https://www.deepdyve.com/lp/oxford-university-press/cervical-cancer-the-second-generation-vaccines-move-forward-lY62IJSvKD
SP - 774
EP - 775
VL - 101
IS - 11
DP - DeepDyve
ER -